A leader in specialty pharmaceutical innovation.

Welcome to Paladin Pharma Inc.

Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin
06/17/2025
MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“APA”) entered with Paladin Pharma Inc., an Endo, Inc. operating company, as announced in March 2025.

An innovative specialty pharmaceutical company

Press Releases

29-Jun-2023
Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada

08-Aug-2022
Paladin Labs Announces Health Canada’s Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy

17-Jan-2022
Paladin Labs Inc. Announces the Launch of Xydalba® (dalbavancin for injection) in Canada

09-Jun-2021
Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada

12-Apr-2021
ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada

05-Jan-2021
Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

22-Oct-2020
Envarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan

23-Oct-2019
Movapo® (apomorphine hydrochloride) for Patients with Advanced Parkinson’s Disease Now Reimbursed in Most Canadian Provinces

31-Jul-2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada

22-Feb-2019
Paladin Labs Inc. Announces Approval of Envarsus PATM (tacrolimus prolonged-release tablets) in Canada

25-Jul-2018
Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada

23-Apr-2018
Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie’s Disease

19-Apr-2018
Paladin Labs Inc. Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring

10-Jun-2015
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada

9- Feb- 2015
Paladin Labs Announces the Canadian Launch of Zincofax® Spray

19-Aug-2013
Paladin Labs Announces the Canadian Launch of Emtrix®

Paladin Pharma is part of Endo, Inc. — a highly focused generics and specialty branded pharmaceutical company. | Learn More